Sign in

Research summary ·

Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This review pooled results from earlier trials of romiplostim in ITP. ITP is an immune disease with low platelets and more bleeding. Each trial gave people romiplostim or a dummy drug by chance. The trials included children and adults, with 748 people in total. The team searched for trials up to March 2026. They also rated how sure they could be of the evidence.

What they found

Romiplostim raised platelet counts more than the dummy drug. This was seen at weeks 2, 4, 6 and 8. The effect was larger in adults. More people had a platelet response with romiplostim. Fewer people needed extra rescue treatment. Side effects were similar in both groups. Muscle pain and rash were slightly more common with romiplostim.

What it means for patients

The authors say romiplostim works for ITP and is well tolerated. It raised platelets and cut the need for rescue treatment. They saw no major safety worries.

Why it is not certain yet

The abstract does not give the evidence ratings or bias results. It does not say how long the trials lasted. It does not give side effect results by age. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.

PubMed · PMID 42559680

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications